Skip to main content

Error message

  • The specified file temporary://fileZsoBsI could not be copied, because the destination directory is not properly configured. This may be caused by a problem with file or directory permissions. More information is available in the system log.
  • The specified file temporary://fileVvkMDK could not be copied, because the destination directory is not properly configured. This may be caused by a problem with file or directory permissions. More information is available in the system log.
  • The specified file temporary://fileRwqV4H could not be copied, because the destination directory is not properly configured. This may be caused by a problem with file or directory permissions. More information is available in the system log.
  • The specified file temporary://filevadKEJ could not be copied, because the destination directory is not properly configured. This may be caused by a problem with file or directory permissions. More information is available in the system log.
  • The specified file temporary://filewKtJZK could not be copied, because the destination directory is not properly configured. This may be caused by a problem with file or directory permissions. More information is available in the system log.
  • The specified file temporary://file33sLBH could not be copied, because the destination directory is not properly configured. This may be caused by a problem with file or directory permissions. More information is available in the system log.
  • The specified file temporary://fileExBZnJ could not be copied, because the destination directory is not properly configured. This may be caused by a problem with file or directory permissions. More information is available in the system log.

Leading scientist Andres Carrasco dies aged 67

Argentinian molecular biologist was a thorn in the side of pesticide giant Monsanto

ARGENTINIAN molecular biologist Andres Carrasco, whose work on the pesticide glyphosate became a major headache for biotechnology conglomerate Monsanto, died this weekend aged 67.

Mr Carrasco, who worked at the University of Buenos Aires and was past president of his country’s science council, was a widely published expert in embryonic development.

His 2010 study on glyphosate thrust him to international prominence, posing a major public-relations challenge to the US transnational corporation.

Glyphosate is the key ingredient in Monsanto’s Roundup brand of pesticides, which have combined with genetically modified “Roundup-Ready” plants to dramatically increase the spread of industrial agriculture round the world.

The US Environmental Protection Agency has labelled it reasonably safe to use if applied properly.

However, Mr Carrasco decided to test the impact of glyphosate on frog and chicken embryos after hearing reports of increasing birth defects in farming communities after genetically modified crops were approved for use in Argentina.

His team’s study, published in the peer-reviewed Chemical Research in Toxicology journal, found that injecting very low doses of glyphosate into embryos can change levels of retinoic acid, causing the same sort of spinal defects that doctors are increasingly registering in communities where farm chemicals are ubiquitous.

Retinoic acid, a form of vitamin A, is fundamental for keeping cancers in check and triggering genetic expression, the process by which embryonic cells develop into organs and limbs.

“If it’s possible to reproduce this in a laboratory, surely what is happening in the field is much worse,” he said, arguing the necessity to “put this under a magnifying glass.”

Monsanto dismissed his results as “not surprising given their methodology and unrealistic exposure scenarios.”

Company spokesman Thomas Helscher said that those methods were “relatively new” and that scientists don’t yet understand “how to translate genetic modulations into predictions of adverse outcome.”

He said that injecting embryos with pesticides was “less reliable and less relevant for human risk assessments” than methods the industry uses.

OWNED BY OUR READERS

We're a reader-owned co-operative, which means you can become part of the paper too by buying shares in the People’s Press Printing Society.

 

 

Become a supporter

Fighting fund

You've Raised:£ 9,899
We need:£ 8,101
12 Days remaining
Donate today